Importance of meta-analysis of long-term trials of low–molecular-weight heparin vs vitamin K antagonist in pulmonary embolism

[...]the idea is to look for a new potential subgroup (noncancer high-risk patients) in PTE/VTE long-term trials of LMWH vs VKA who may have significantly better response to LMWH (in comparison to VKA), as already demonstrated for cancer patients.

Saved in:
Bibliographic Details
Published in:The American journal of emergency medicine 2013-03, Vol.31 (3), p.627-628
Main Author: Koracevic, Goran P.
Format: Article
Language:English
Subjects:
Advantages
Anticoagulants
Anticoagulants - therapeutic use
Cancer
Drug therapy
Emergency
Emergency medical care
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Meta-Analysis as Topic
Pulmonary Embolism - prevention & control
Secondary Prevention
Vitamin K - antagonists & inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c390t-3f8f27f9ba6403dda5e9f1344b02941f916a4ed0431f2aa94a0426b0c4d77b833
container_end_page 628
container_issue 3
container_start_page 627
container_title The American journal of emergency medicine
container_volume 31
creator Koracevic, Goran P.
description [...]the idea is to look for a new potential subgroup (noncancer high-risk patients) in PTE/VTE long-term trials of LMWH vs VKA who may have significantly better response to LMWH (in comparison to VKA), as already demonstrated for cancer patients.
doi_str_mv 10.1016/j.ajem.2012.12.012
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1316053849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0735675712006511</els_id><sourcerecordid>1316053849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-3f8f27f9ba6403dda5e9f1344b02941f916a4ed0431f2aa94a0426b0c4d77b833</originalsourceid><addsrcrecordid>eNp9Uk2LFDEQbURxx9U_4EEavHjpMZWkv0AEWfxYXPCgnkM6XT2bNum0SXqWOel_8B_6S0w7o8IehIJKivcevHqVZY-BbIFA9XzcyhHtlhKg21Sp3ck2UDJaNFDD3WxDalYWVV3WZ9mDEEZCAHjJ72dnlDFWQ91ssm-XdnY-yklh7obcYpSFnKQ5BB3WgXHTrojobR69luY0u_n5_Yd1BtVipC9uUO-uY36Ns_R6yvch3-sobXq-z-UU5c5NOsQ8_efFWDdJf8jRds7oYB9m94Yki49O_Tz7_Ob1p4t3xdWHt5cXr64KxVoSCzY0A62HtpMVJ6zvZYntAIzzjtCWw9BCJTn2hDMYqJQtl4TTqiOK93XdNYydZ8-OurN3XxcMUVgdFBojJ3RLEMCgIiVreJugT29BR7f4tJPfqJJCWi4kFD2ilHcheBzE7LVN1gQQscYjRrHGI9Z4RKrUEunJSXrpLPZ_KX_ySIAXRwCmXew1ehGUxhROrz2qKHqn_6__8hZdGT1pJc0XPGD450OERBAf1wNZ7wMoIVWZXP0C9mq3mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1315211711</pqid></control><display><type>article</type><title>Importance of meta-analysis of long-term trials of low–molecular-weight heparin vs vitamin K antagonist in pulmonary embolism</title><source>ScienceDirect Freedom Collection</source><creator>Koracevic, Goran P.</creator><creatorcontrib>Koracevic, Goran P.</creatorcontrib><description>[...]the idea is to look for a new potential subgroup (noncancer high-risk patients) in PTE/VTE long-term trials of LMWH vs VKA who may have significantly better response to LMWH (in comparison to VKA), as already demonstrated for cancer patients.</description><identifier>ISSN: 0735-6757</identifier><identifier>EISSN: 1532-8171</identifier><identifier>DOI: 10.1016/j.ajem.2012.12.012</identifier><identifier>PMID: 23337178</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Advantages ; Anticoagulants ; Anticoagulants - therapeutic use ; Cancer ; Drug therapy ; Emergency ; Emergency medical care ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Meta-Analysis as Topic ; Pulmonary Embolism - prevention &amp; control ; Secondary Prevention ; Vitamin K - antagonists &amp; inhibitors</subject><ispartof>The American journal of emergency medicine, 2013-03, Vol.31 (3), p.627-628</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright Elsevier Limited 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c390t-3f8f27f9ba6403dda5e9f1344b02941f916a4ed0431f2aa94a0426b0c4d77b833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23337178$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koracevic, Goran P.</creatorcontrib><title>Importance of meta-analysis of long-term trials of low–molecular-weight heparin vs vitamin K antagonist in pulmonary embolism</title><title>The American journal of emergency medicine</title><addtitle>Am J Emerg Med</addtitle><description>[...]the idea is to look for a new potential subgroup (noncancer high-risk patients) in PTE/VTE long-term trials of LMWH vs VKA who may have significantly better response to LMWH (in comparison to VKA), as already demonstrated for cancer patients.</description><subject>Advantages</subject><subject>Anticoagulants</subject><subject>Anticoagulants - therapeutic use</subject><subject>Cancer</subject><subject>Drug therapy</subject><subject>Emergency</subject><subject>Emergency medical care</subject><subject>Heparin, Low-Molecular-Weight - therapeutic use</subject><subject>Humans</subject><subject>Meta-Analysis as Topic</subject><subject>Pulmonary Embolism - prevention &amp; control</subject><subject>Secondary Prevention</subject><subject>Vitamin K - antagonists &amp; inhibitors</subject><issn>0735-6757</issn><issn>1532-8171</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9Uk2LFDEQbURxx9U_4EEavHjpMZWkv0AEWfxYXPCgnkM6XT2bNum0SXqWOel_8B_6S0w7o8IehIJKivcevHqVZY-BbIFA9XzcyhHtlhKg21Sp3ck2UDJaNFDD3WxDalYWVV3WZ9mDEEZCAHjJ72dnlDFWQ91ssm-XdnY-yklh7obcYpSFnKQ5BB3WgXHTrojobR69luY0u_n5_Yd1BtVipC9uUO-uY36Ns_R6yvch3-sobXq-z-UU5c5NOsQ8_efFWDdJf8jRds7oYB9m94Yki49O_Tz7_Ob1p4t3xdWHt5cXr64KxVoSCzY0A62HtpMVJ6zvZYntAIzzjtCWw9BCJTn2hDMYqJQtl4TTqiOK93XdNYydZ8-OurN3XxcMUVgdFBojJ3RLEMCgIiVreJugT29BR7f4tJPfqJJCWi4kFD2ilHcheBzE7LVN1gQQscYjRrHGI9Z4RKrUEunJSXrpLPZ_KX_ySIAXRwCmXew1ehGUxhROrz2qKHqn_6__8hZdGT1pJc0XPGD450OERBAf1wNZ7wMoIVWZXP0C9mq3mw</recordid><startdate>20130301</startdate><enddate>20130301</enddate><creator>Koracevic, Goran P.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130301</creationdate><title>Importance of meta-analysis of long-term trials of low–molecular-weight heparin vs vitamin K antagonist in pulmonary embolism</title><author>Koracevic, Goran P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-3f8f27f9ba6403dda5e9f1344b02941f916a4ed0431f2aa94a0426b0c4d77b833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Advantages</topic><topic>Anticoagulants</topic><topic>Anticoagulants - therapeutic use</topic><topic>Cancer</topic><topic>Drug therapy</topic><topic>Emergency</topic><topic>Emergency medical care</topic><topic>Heparin, Low-Molecular-Weight - therapeutic use</topic><topic>Humans</topic><topic>Meta-Analysis as Topic</topic><topic>Pulmonary Embolism - prevention &amp; control</topic><topic>Secondary Prevention</topic><topic>Vitamin K - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koracevic, Goran P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koracevic, Goran P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Importance of meta-analysis of long-term trials of low–molecular-weight heparin vs vitamin K antagonist in pulmonary embolism</atitle><jtitle>The American journal of emergency medicine</jtitle><addtitle>Am J Emerg Med</addtitle><date>2013-03-01</date><risdate>2013</risdate><volume>31</volume><issue>3</issue><spage>627</spage><epage>628</epage><pages>627-628</pages><issn>0735-6757</issn><eissn>1532-8171</eissn><abstract>[...]the idea is to look for a new potential subgroup (noncancer high-risk patients) in PTE/VTE long-term trials of LMWH vs VKA who may have significantly better response to LMWH (in comparison to VKA), as already demonstrated for cancer patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23337178</pmid><doi>10.1016/j.ajem.2012.12.012</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0735-6757
ispartof The American journal of emergency medicine, 2013-03, Vol.31 (3), p.627-628
issn 0735-6757
1532-8171
language eng
recordid cdi_proquest_miscellaneous_1316053849
source ScienceDirect Freedom Collection
subjects Advantages
Anticoagulants
Anticoagulants - therapeutic use
Cancer
Drug therapy
Emergency
Emergency medical care
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Meta-Analysis as Topic
Pulmonary Embolism - prevention & control
Secondary Prevention
Vitamin K - antagonists & inhibitors
title Importance of meta-analysis of long-term trials of low–molecular-weight heparin vs vitamin K antagonist in pulmonary embolism
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T04%3A54%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Importance%20of%20meta-analysis%20of%20long-term%20trials%20of%20low%E2%80%93molecular-weight%20heparin%20vs%20vitamin%20K%20antagonist%20in%20pulmonary%20embolism&rft.jtitle=The%20American%20journal%20of%20emergency%20medicine&rft.au=Koracevic,%20Goran%20P.&rft.date=2013-03-01&rft.volume=31&rft.issue=3&rft.spage=627&rft.epage=628&rft.pages=627-628&rft.issn=0735-6757&rft.eissn=1532-8171&rft_id=info:doi/10.1016/j.ajem.2012.12.012&rft_dat=%3Cproquest_cross%3E1316053849%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-3f8f27f9ba6403dda5e9f1344b02941f916a4ed0431f2aa94a0426b0c4d77b833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1315211711&rft_id=info:pmid/23337178&rfr_iscdi=true